Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Investment Securities (2017 - 2024)

Historic Gains from Investment Securities for Puma Biotechnology (PBYI) over the last 8 years, with Q3 2024 value amounting to $441430.0.

  • Puma Biotechnology's Gains from Investment Securities fell 2410.26% to $441430.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $441430.0, marking a year-over-year decrease of 2410.26%. This contributed to the annual value of $581614.0 for FY2023, which is 12.69% down from last year.
  • Latest data reveals that Puma Biotechnology reported Gains from Investment Securities of $441430.0 as of Q3 2024, which was down 2410.26% from $441430.0 recorded in Q2 2024.
  • Puma Biotechnology's 5-year Gains from Investment Securities high stood at $5.4 million for Q1 2020, and its period low was -$1000.0 during Q4 2021.
  • Over the past 5 years, Puma Biotechnology's median Gains from Investment Securities value was $581614.0 (recorded in 2023), while the average stood at $2.0 million.
  • As far as peak fluctuations go, Puma Biotechnology's Gains from Investment Securities soared by 53629870.0% in 2020, and later plummeted by 10153.85% in 2021.
  • Quarter analysis of 5 years shows Puma Biotechnology's Gains from Investment Securities stood at $65000.0 in 2020, then crashed by 101.54% to -$1000.0 in 2021, then surged by 58335.3% to $582353.0 in 2022, then fell by 0.13% to $581614.0 in 2023, then fell by 24.1% to $441430.0 in 2024.
  • Its Gains from Investment Securities stands at $441430.0 for Q3 2024, versus $441430.0 for Q2 2024 and $441430.0 for Q1 2024.